|Bid||29.47 x 900|
|Ask||29.74 x 1100|
|Day's Range||28.96 - 29.64|
|52 Week Range||25.76 - 42.25|
|Beta (3Y Monthly)||1.40|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||43.67|
LONDON, Oct. 18, 2018 -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated a Phase I study of HMPL-523, its novel spleen tyrosine kinase (“Syk”).
Hutchison China MediTech has won Chinese approval for a closely watched new cancer drug in a significant boost for "made in China" medicine. The London-listed company - which is known as Chi-Med and is collaborating with Eli Lilly on the drug - said on Wednesday that the National Medical Products Administration of China had approved Elunate or fruquintinib in colorectal cancer. It is one of the first modern medicines discovered and developed in China, and the speedy green light from Chinese authorities is further evidence of the country's progress in speeding up drug approvals.
–Fruquintinib capsules provide a new oral treatment option for patients with metastatic colorectal cancer and will be marketed as Elunate ®–. –Elunate ® data published in JAMA demonstrated increased overall ...
Hutchison China Meditech CEO Christian Hogg discusses the importance of capitalizing on opportunities and shares his outlook for biotech. (Source: Bloomberg)
NEW YORK, NY / ACCESSWIRE / July 27, 2018 / Hutchison China MediTech Limited Sponsored ADR (NASDAQ: HCM ) will be discussing their earnings results in their H1 Earnings Call to be held on July 27, 2018 ...
LONDON, July 27, 2018-- Hutchison China MediTech Limited today announces its unaudited financial results for the six months ended June 30, 2018 and updates shareholders on key clinical programs. Fruquintinib ...
Does the share price for Hutchison China MediTech Limited (AIM:HCM) reflect it’s really worth? Today, I will calculate the stock’s intrinsic value using the discounted cash flow (DCF) method. IfRead More...
NEW YORK , March 16, 2018 /PRNewswire/ -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference ("dbVIC") on March 21 st and 22 nd , featuring live ...
Small-cap and large-cap companies receive a lot of attention from investors, but mid-cap stocks like Hutchison China MediTech Limited (NASDAQ:HCM), with a market cap of US$4.50B, are often out ofRead More...
Hutchison China MediTech Limited has initiated a Phase Ib/II proof-of-concept study of epitinib in glioblastoma patients with epidermal growth factor receptor gene amplification in China.
Investors tend to look for stocks that have a strong future outlook. Why invest in something that will grow slower than the rest of the market? In terms of profitabilityRead More...
Hutchison China MediTech Limited has completed patient enrollment of FALUCA, its Phase III pivotal trial of fruquintinib in advanced, third-line, non-small cell lung cancer patients in China.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Hutchison China MediTech Ltd. Here are 5 ETFs with the largest exposure to HCM-US. Comparing the performance and risk of Hutchison China MediTech Ltd. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower ... Read more (Read more...)
Hutchison China MediTech Limited has initiated the United States Phase I bridging clinical trial of fruquintinib. Fruquintinib is a highly selective and potent oral inhibitor of vascular endothelial growth factor receptors 1, 2 and 3, that has met its primary endpoint in several Phase II and III clinical trials in China for the treatment of colorectal, lung and gastric cancers.
Hutchison China MediTech Limited’s (NASDAQ:HCM) most recent return on equity was a substandard 7.52% relative to its industry performance of 16.15% over the past year. HCM’s results could indicate aRead More...
Hutchison China MediTech Limited has initiated FRUTIGA, a pivotal Phase III clinical trial of fruquintinib in combination with paclitaxel for the treatment in advanced gastric or gastroesophageal junction adenocarcinoma patients in China.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURI
China-based cancer and immunology drug specialist Hutchison China MediTech, or Chi-Med, said it aimed to offer $262 million of American Depositary Shares, subject to market conditions, to help fund development ...
Hutchison China MediTech Limited announced today that it intends to offer, subject to market and other conditions, US$262.0 million of American Depositary Shares , each representing one-half of one ordinary share, par value US$1.00 each of Chi-Med , on the Nasdaq Global Select Market .